years
patients
ovarian cancer
treated with
combination
cisplatinum
CPDD
adriamycin
cyclophosphamide
day
hexamethylmelamine
HMM
daily
days
course
monthly
patients
stage II
stage III
stage IV disease
patients
treated with
chemotherapy
radiation
chemotherapy
radiation
treatment
CPDD
combination
cases
objective
responses
months
responses
partial
cases
Hematologic toxicity
moderate
anemia
patients
Gastrointestinal side effects
CPDD
HMM
gastrointestinal
toxicity
discontinuation
drug
patients
Severe
nephrotoxicity
patients
reversible
drug-related deaths
